Novartis has submitted NVA237, the company’s new treatment for chronic obstructive pulmonary disease, for approval in Japan.

The drug, which was submitted for European approval in September 2011 under the brand name Seebri Breezhaler, is a long-acting muscarinic antagonist designed to be taken once-daily.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Novartis originally licensed the drug from Japanese pharmaceutical company Sosei and UK-based Vectura in April 2005.

Novartis last week signed Eisai as a co-promoter of the drug should it receive Japanese approval.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
NorthWest EHealth has won three 2025 Pharmaceutical Technology Excellence Awards for Innovation, Safety and Diversity. Explore how its ConneXon platform is transforming SAE reporting and real-time safety oversight, while FARSITE delivers socio-economically inclusive recruitment to boost trial efficiency, data integrity and regulatory-grade representativeness.

Discover the Impact